Ileocolic Crohn's disease associated to diffuse mesenteric involvement mimicking metastatic colorectal cancer

2011 ◽  
Vol 17 (suppl_1) ◽  
pp. S41-S41
Author(s):  
I Cardoso ◽  
G Santana ◽  
A Mello ◽  
S Leite ◽  
V Surlo ◽  
...  
2017 ◽  
Vol 37 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Sandra Cristina Dias dos Santos ◽  
Laura Elisabete Ribeiro Barbosa

2016 ◽  
pp. 131-150
Author(s):  
Hiroki Ikeuchi ◽  
Motoi Uchino ◽  
Toshihiro Bando ◽  
Kei Hirose ◽  
Nobuyuki Hida ◽  
...  

Author(s):  
Hajime Tanaka ◽  
Sivagami Gunasekaran ◽  
Dina Mourad Saleh ◽  
William Theodore Alexander ◽  
David Bedell Alexander ◽  
...  

Both ulcerative colitis and colonic Crohn's disease patients have a significantly increased risk of developing colorectal cancer. bLF is reported to inhibit the development of colon cancer in rats and mice, and in a placebo controlled trial, ingestion of bLF inhibited the growth of intestinal polyps. In addition, in a case study a Crohn's disease patient was reported to have remained in remission for over 7 years while ingesting 1 gram of bLF daily. Thus, bLF has an inhibitory effect on colon carcinogenesis, and it may also promote remission of Crohn's disease. The purpose of the present study was to begin to investigate the effect of bLF on a mouse model of IBD-related colorectal cancer. Azoxymethane (AOM) was used to initiate intestinal cancer and dextran sulfate sodium (DSS) was used to induce IBD-like inflammation in the intestine of C57BL/6 mice. Mice were divided into 4 groups: untreated, bLF alone, AOM+DSS, and AOM+DSS+bLF. At the end of the study, mice given AOM+DSS+LF had a better fecal score, less wounding in the colon, and less weight loss than mice in the AOM+DSS group. However, there were no statistically significant differences between the two groups in tumor burden.


2014 ◽  
Vol 10 (9) ◽  
pp. 2317 ◽  
Author(s):  
Jing Bai ◽  
Yongsheng Li ◽  
Tingting Shao ◽  
Zheng Zhao ◽  
Yuan Wang ◽  
...  

Gut ◽  
1994 ◽  
Vol 35 (5) ◽  
pp. 651-655 ◽  
Author(s):  
C D Gillen ◽  
H A Andrews ◽  
P Prior ◽  
R N Allan

2021 ◽  
Vol 10 (20) ◽  
pp. 4663
Author(s):  
Hyunil Kim ◽  
Ji Hoon Kim ◽  
Jung Kuk Lee ◽  
Dae Ryong Kang ◽  
Su Young Kim ◽  
...  

We investigated the risk of colorectal cancer (CRC) in patients with Crohn’s disease (CD) using the claims data of the Korean National Health Insurance during 2006–2015. The data of 13,739 and 40,495 individuals with and without CD, respectively, were analyzed. Hazard ratios (HRs) were calculated using multivariate Cox proportional hazard regression tests. CRC developed in 25 patients (0.18%) and 42 patients (0.1%) of the CD and non-CD groups, respectively. The HR of CRC in the CD group was 2.07 (95% confidence interval (CI), 1.25–3.41). The HRs of CRC among men and women were 2.02 (95% CI 1.06–3.87) and 2.10 (95% CI, 0.96–4.62), respectively. The HRs of CRC in the age groups 0–19, 20–39, 40–59, and ≥60 years were 0.07, 4.86, 2.32, and 0.66, respectively. The HR of patients with late-onset CD (≥40 years) was significantly higher than that of those with early-onset CD (<40 years). CD patients were highly likely to develop CRC. Early-onset CD patients were significantly associated with an increased risk of CRC than matched individuals without CD. However, among CD patients, late-onset CD was significantly associated with an increased risk of CRC.


2020 ◽  
Vol 5 (5) ◽  
pp. 475-484 ◽  
Author(s):  
Ola Olén ◽  
Rune Erichsen ◽  
Michael C Sachs ◽  
Lars Pedersen ◽  
Jonas Halfvarson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document